Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin

Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections

(2011) S. L. Holt et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum

(2011) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin ResistanceIn Vivo

(2011) Keunsook K. Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Current perspectives on echinocandin class drugs

(2011) David S Perlin   Future Microbiology

Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital

(2011) I. Miranda-Zapico et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species ofCandida

(2011) Michael A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

CandidaBloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

(2010) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four DifferentCandidaSpecies

(2010) Fernando C. Bizerra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Echinocandin Antifungal Drugs in Fungal Infections

(2010) Sharon C.-A. Chen et al.   DRUGS

In Vitro Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fungal echinocandin resistance

(2009) Louise A. Walker et al.   FUNGAL GENETICS AND BIOLOGY

Paradoxical echinocandin activity: a limitedin vitrophenomenon?

(2009) Nathan P. Wiederhold   MEDICAL MYCOLOGY

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

(2008) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Functional analysis of Candida albicans GPI-anchored proteins: Roles in cell wall integrity and caspofungin sensitivity

(2008) Armêl Plaine et al.   FUNGAL GENETICS AND BIOLOGY

Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins

(2008) Louise A. Walker et al.   PLoS Pathogens